ABUS (Arbutus Biopharma) Moat Score: 3/10 (As of Jun. 27, 2026)


ABUS Arbutus Biopharma Corp ABUS
51 GF Score
Price $4.57
GF Value $51.39
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Moat Score?

Arbutus Biopharma ABUS +3.74% 51 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $51.39 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,404 Biotechnology companies, Arbutus Biopharma ranks better than 75.5% on this metric.

Arbutus Biopharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Arbutus Biopharma has No Moat: Arbutus Biopharma Corp has some intellectual property in the biotech sector, but it lacks market leadership, strong brand loyalty, or significant regulatory barriers. The competitive nature of the industry and limited customer switching costs result in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Arbutus Biopharma might have No Moat - Very weak/transient advantages.

Arbutus Biopharma  (NAS:ABUS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Arbutus Biopharma Moat Score Related Terms

ABUS vs SPRY, KURA, JANX: Moat Score Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Moat Score falls into.


ABUS
51GF Score
Arbutus Biopharma Corp ABUS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Arbutus Biopharma (ABUS) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Arbutus Biopharma ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Arbutus Biopharma's Moat Score too high?
Arbutus Biopharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Arbutus Biopharma's value of 3 is 50% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Moat Score compare to SPRY and KURA?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #344 out of 1404 companies for Moat Score. This places Arbutus Biopharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Arbutus Biopharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.39, compared to a current price of $4.57 — trading 91.1% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.57 is trading 91.1% below its estimated GF Value™ of $51.39. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Moat Score: 3
  • GF Value™: $51.39 vs. price of $4.57 (91.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#344 of 1404)

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score

Get the complete analysis for ABUS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.57
Price
$51.39
GF Value